Aflac stock (US0010551028): recent earnings, revenue jump and what matters for US investors

Aflac shares have gained in 2026 as the insurer reported a sharp year?over?year revenue increase but slightly missed first?quarter EPS estimates. Here is what the latest numbers and business mix mean for investors following the New York–listed stock.

Aflac stock has been trading moderately higher in 2026, with the New York–listed shares changing hands at about 116.83 USD at the close on 05/15/2026 on the NYSE, up roughly 5.9% since the start of the year, according to MarketBeat as of 05/15/2026. The move follows a first?quarter earnings release that delivered nearly 28% revenue growth but came in a few cents shy of analyst EPS expectations, as summarized by MarketBeat as of 05/15/2026.

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AFLAC Inc.
• Sector/industry: Insurance, supplemental health and life
• Headquarters/country: Columbus, Georgia, United States
• Core markets: United States and Japan
• Key revenue drivers: Supplemental health policies, life insurance, cancer and medical products, investment income
• Home exchange/listing venue: New York Stock Exchange (ticker: AFL)
• Trading currency: US dollar (USD)

Aflac: core business model

Aflac is best known in the United States for its supplemental insurance offerings, which are designed to help policyholders cover out?of?pocket expenses that primary health or life insurance does not fully reimburse. The company collects premiums from individuals and employers, invests those funds in a fixed?income?heavy portfolio and pays claims when covered events occur.

The business has long been built around two main geographic segments: the United States and Japan. The Japanese operations focus heavily on third?sector products such as cancer and medical policies, which complement Japan’s national health insurance system. In the US, Aflac markets workplace voluntary benefits and individual supplemental coverage that sit alongside employer health plans.

This model generates revenue from insurance premiums and investment income on the company’s asset portfolio. Profitability depends on underwriting discipline—keeping the combined ratio and benefit ratios in check—as well as prudent asset?liability management. Given the long?duration nature of many policies, interest?rate movements and credit spreads can materially influence earnings over time.

Aflac distributes many of its products through partnerships with employers, financial institutions and independent agents. In Japan, bancassurance partners and alliances with large banks have historically been important distribution channels. In the US, brokers and enrollment platforms help the company reach employees at small and large companies seeking to enhance benefit packages.

Main revenue and product drivers for Aflac

Recent financial commentary highlights that Aflac’s revenue grew by nearly 28% year over year in the latest reported quarter, reflecting a mix of premium growth and the impact of currency and investment results, according to MarketBeat as of 05/15/2026. The insurer reported quarterly earnings per share of 1.75 USD, missing the consensus estimate of 1.80 USD by 0.05 USD, as summarized by MarketBeat as of 05/15/2026.

Premiums from supplemental health, cancer and medical policies form a major component of Aflac’s top line. In Japan, products addressing cancer, hospitalization and nursing care needs have been core offerings for decades, and policy persistency tends to be relatively high. In the US, accident, critical illness, hospital indemnity and short?term disability coverage drive a large share of premiums, with cross?selling opportunities emerging when employers expand voluntary benefit menus.

Investment income is another important revenue stream. Aflac invests its float—premiums received but not yet paid out as claims—in a portfolio that typically emphasizes high?grade bonds and other fixed?income securities to match liability profiles. Changes in interest rates can influence both the yield earned on new investments and the market value of existing holdings, affecting reported results and capital ratios.

On the expense side, benefits and claims, acquisition costs and general operating expenses are key drivers of profitability. A modest EPS shortfall in the latest quarter suggests that either claims experience, expenses or investment results differed slightly from consensus expectations. However, the strong year?over?year revenue growth underscores that the company is still expanding its premium base despite a mature footprint in its core markets.

Why Aflac matters for US investors

For US investors, Aflac represents exposure to the supplemental insurance niche, which tends to be less commoditized than standard life or property?casualty lines. The stock trades on the New York Stock Exchange under the ticker AFL, making it accessible to US brokerage accounts and retirement plans. Its earnings are influenced by both US and Japanese economic conditions, providing a blend of domestic and international insurance exposure.

Because of its long record as a dividend payer, Aflac is often tracked by income?oriented investors who monitor payout ratios, dividend growth and capital return policies. The company has also been active with share repurchases over the years, though any current buyback details would need to be confirmed with the latest disclosures. In addition, the insurer’s capital position and regulatory environment in the US and Japan are closely watched, as solvency considerations are central for financial institutions.

The stock’s performance year to date—up roughly 5.9% from 110.31 USD at the start of 2026 to 116.83 USD in mid?May, according to MarketBeat as of 05/15/2026—illustrates how investors have digested the latest earnings and macro signals. While short?term price moves can be influenced by interest?rate expectations and sector rotation, the underlying business remains tied to insured event frequency, persistency of in?force policies and the company’s ability to underwrite profitably.

Conclusion

Aflac’s latest quarter combined a notable near?28% year?over?year revenue increase with a small EPS miss versus consensus, while the share price has advanced modestly so far in 2026. The insurer remains anchored in supplemental health and life products across the US and Japan, with results shaped by underwriting outcomes and investment returns. For US investors following the financial sector, the stock offers exposure to a relatively specialized insurance niche, and future performance will likely hinge on capital deployment, interest?rate trends and the company’s ability to sustain profitable premium growth.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.